Acotif 300 contains Acotiamide Hydrochloride Hydrate, a first-in-class prokinetic agent and the world’s first approved treatment for Postprandial Distress Syndrome (PDS) — a key symptom cluster of Functional Dyspepsia (FD).
CALBRICK-D3 is a high-strength Vitamin D₃ (Cholecalciferol) supplement delivering 60,000 IU per sachet. As a crucial fat-soluble vitamin, it supports calcium and phosphorus absorption, promotes bone mineralization, regulates immune response, and maintains metabolic balance.
Formulated as granulated sachets, CALBRICK-D3 ensures easy weekly dosing, excellent patient compliance, and effective management of Vitamin D deficiency.
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
The combination Amoxicillin + Clavulanic Acid + Lactic Acid Bacillus is a triple formulation that includes two drug components and one probiotic. Here’s a clear breakdown
a) Amoxicillin
A broad-spectrum penicillin-type (β-lactam) antibiotic.
It works by inhibiting bacterial cell wall synthesis, leading to bacterial death.
Active against many Gram-positive and some Gram-negative bacteria.
b) Clavulanic Acid
A β-lactamase inhibitor (similar role to tazobactam).
It prevents bacterial enzymes (β-lactamases) from destroying amoxicillin, making the antibiotic more effective against resistant strains.
c) Lactic Acid Bacillus
A probiotic (friendly bacteria) added to prevent or reduce antibiotic-associated diarrhea and restore the natural gut flora disturbed by antibiotics.
